APPLICATIONS OF TECHNOLOGY:
- Treatment of radionuclide exposure
- Treatment or prevention of gadolinium (Gd) deposition from MRIs
- Treatment for exposure to toxic metals including lead (Pb), tin (Sn), and cadmium (Cd)
- Administered orally in a variety of dosage forms
- Ease of clinical use
- Enables use during emergencies or mass casualty
Researchers at Berkeley Lab have developed oral dosage forms for the decorporation agent 3,4,3-LI(1,2-HOPO) including powder in bottles, granules, chewable tablets, conventional tablets, and capsules. These dosage forms enable easy administration to contaminated individuals in an emergency or clinical setting.
In tests, the Berkeley Lab decorporation agent had a high affinity for lanthanides in comparison to the commonly used diethylenetriamine-pentaacetic acid (DTPA). As a result, 3,4,3-LI(1,2-HOPO) may become a therapeutic chelating agent for gadolinium, which is used in MRI contrast agents. The Berkeley Lab decorporation agent has greatly progressed in terms of oral bioavailability and has the potential to become a therapeutic metal chelating agent that can be used in clinics, emergencies, and in mass casualty scenarios.
Based on their respective physico-chemical properties and stabilities, every proposed oral dosage form prototype is suitable. By contrast, the standard therapy for actinide/lanthanide decorporation must be administered intravenously or by nebulizer, making it challenging to use in a mass casualty or emergency situation.
DEVELOPMENT STAGE: Proven principle
FOR MORE INFORMATION:
Sturzbecher-Hoehne, M., Leung, C., D’Aleo, A., Kullgren, B., Prigent, A-L, Shuh, D., Raymond, K., and Abergel, R. “3,4,3-LI(1,2-HOPO): In vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation,” The Royal Society of Chemistry, 2011, 40, 8340-8346.
STATUS: Published PCT Patent Application US2017/050121 (Publication WO/2018/048812). Available for licensing or collaborative research.
SEE THESE OTHER BERKELEY LAB TECHNOLOGIES IN THIS FIELD